SAB Biotherapeutics Files 8-K on Stock and Warrants

TL;DR

SAB Biotherapeutics (SABS) filed an 8-K detailing common stock and $11.50 warrants.

AI Summary

SAB Biotherapeutics, Inc. filed an 8-K on April 15, 2024, reporting an event on April 12, 2024. The filing pertains to their common stock and warrants, with specific details about warrants exercisable for one share of common stock at an exercise price of $11.50 per share. The company was formerly known as Big Cypress Acquisition Corp. and changed its name on November 20, 2020.

Why It Matters

This filing provides an update on the company's capital structure, specifically concerning its common stock and outstanding warrants, which could impact existing shareholders and potential investors.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate actions and does not indicate immediate financial distress or significant operational changes.

Key Numbers

• $11.50 — Warrant Exercise Price (Price at which warrants can be exercised for common stock.)

Key Players & Entities

• SAB Biotherapeutics, Inc. (company) — Registrant
• Big Cypress Acquisition Corp. (company) — Former company name
• April 12, 2024 (date) — Earliest event date
• April 15, 2024 (date) — Date of report
• $11.50 (dollar_amount) — Warrant exercise price

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq

Filing Documents

• sabs-20240412.htm (8-K) — 43KB
• 0000950170-24-044497.txt ( ) — 200KB
• sabs-20240412.xsd (EX-101.SCH) — 50KB
• sabs-20240412_htm.xml (XML) — 8KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 12, 2024, SAB Biotherapeutics, Inc., a Delaware corporation (the "Company" or "SAB"), announced that it had completed dosing of cohort 3 for phase one trials of SAB-142 and has not observed any instances of serum sicknesses. The Company intends to issue a press release with a corporate update on or about April 16, 2024. Cautionary Note Regarding Forward-Looking Statements Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "to be," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our T1D program, and other discovery programs, the closing of each tranche of the Company's private placement offering, the timely funding to the Company by each investor in the private placement offering, financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government, and other third-party collaborations or funded programs. These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: April 15, 2024 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR